{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:38:45Z","timestamp":1777599525676,"version":"3.51.4"},"reference-count":37,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Background: Voriconazole is one of the first-line therapies for invasive pulmonary aspergillosis. Drug concentrations might be significantly influenced by the use of extracorporeal membrane oxygenation (ECMO). We aimed to assess the effect of ECMO on voriconazole exposure in a large patient population. Methods: Critically ill patients from eight centers in four countries treated with voriconazole during ECMO support were included in this retrospective study. Voriconazole concentrations were collected in a period on ECMO and before\/after ECMO treatment. Multivariate analyses were performed to evaluate the effect of ECMO on voriconazole exposure and to assess the impact of possible saturation of the circuit\u2019s binding sites over time. Results: Sixty-nine patients and 337 samples (190 during and 147 before\/after ECMO) were analyzed. Subtherapeutic concentrations (&lt;2 mg\/L) were observed in 56% of the samples during ECMO and 39% without ECMO (p = 0.80). The median trough concentration, for a similar daily dose, was 2.4 (1.2\u20134.7) mg\/L under ECMO and 2.5 (1.4\u20133.9) mg\/L without ECMO (p = 0.58). Extensive inter-and intrasubject variability were observed. Neither ECMO nor squared day of ECMO (saturation) were retained as significant covariates on voriconazole exposure. Conclusions: No significant ECMO-effect was observed on voriconazole exposure. A large proportion of patients had voriconazole subtherapeutic concentrations.<\/jats:p>","DOI":"10.3390\/microorganisms9071543","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T23:19:51Z","timestamp":1626823191000},"page":"1543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation"],"prefix":"10.3390","volume":"9","author":[{"given":"Ruth","family":"Van Daele","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium"},{"name":"Pharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britt","family":"Bekkers","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattias","family":"Lindfors","sequence":"additional","affiliation":[{"name":"ECMO Centre Karolinska, Department of Pediatric Perioperative Medicine and Intensive Care, Karolinska University Hospital, 17177 Stockholm, Sweden"},{"name":"Department of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4124-4581","authenticated-orcid":false,"given":"Lars Mikael","family":"Broman","sequence":"additional","affiliation":[{"name":"ECMO Centre Karolinska, Department of Pediatric Perioperative Medicine and Intensive Care, Karolinska University Hospital, 17177 Stockholm, Sweden"},{"name":"Department of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Schauwvlieghe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, 3015 CP Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Rijnders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, 3015 CP Rotterdam, The Netherlands"},{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, 3015 CP Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole G. M.","family":"Hunfeld","sequence":"additional","affiliation":[{"name":"Department of Intensive Care and Department of Hospital Pharmacy, Erasmus University Medical Center, 3015 CP Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole P.","family":"Juffermans","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Silvio","family":"Taccone","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (ULB), 1050 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Ant\u00f4nio","family":"Coimbra Sousa","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (ULB), 1050 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc-Marie","family":"Jacquet","sequence":"additional","affiliation":[{"name":"Cardiovascular Intensive Care, Cliniques Universitaires Saint-Luc, 1050 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5712-7449","authenticated-orcid":false,"given":"Pierre-Fran\u00e7ois","family":"Laterre","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Cliniques Universitaires St-Luc, Universit\u00e9 Catholique de Louvain, 1050 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9428-3467","authenticated-orcid":false,"given":"Eric","family":"Nulens","sequence":"additional","affiliation":[{"name":"Laboratory Medicine, Medical Microbiology, Algemeen Ziekenhuis Sint-Jan, Brugge-Oostende, 8000 Brugge, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Grootaert","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Algemeen Ziekenhuis Sint-Jan Brugge-Oostende AV, 8000 Brugge, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifa","family":"Lyster","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Royal Brompton & Harefield Hospitals, London SW3 6NP, UK"},{"name":"Cardiothoracic Transplant Unit, Royal Brompton & Harefield Hospitals, London SW3 6NP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Reed","sequence":"additional","affiliation":[{"name":"Cardiothoracic Transplant Unit, Royal Brompton & Harefield Hospitals, London SW3 6NP, UK"},{"name":"Imperial College London, London SW3 6NP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brijesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Anaesthetics, Pain Medicine & Intensive Care, Department of Surgery & Cancer, Faculty of Medicine, Imperial College, London SW3 6NP, UK"},{"name":"Department of Adult Intensive Care, The Royal Brompton and Harefield Hospitals, London SW3 6NP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Meersseman","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-8297","authenticated-orcid":false,"given":"Yves","family":"Debaveye","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium"},{"name":"Intensive Care Unit, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven, 3000 Leuven, Belgium"},{"name":"Medical Intensive Care Unit, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-6400","authenticated-orcid":false,"given":"Christophe","family":"Vandenbriele","sequence":"additional","affiliation":[{"name":"Department of Adult Intensive Care, The Royal Brompton and Harefield Hospitals, London SW3 6NP, UK"},{"name":"Department of Cardiovascular Sciences, KU Leuven, 3000 Leuven, Belgium"},{"name":"Department of Cardiovascular Diseases, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium"},{"name":"Pharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/1469-0691.12426","article-title":"Management and diagnostic guidelines for fungal diseases in infectious diseases and clinical microbiology: Critical appraisal","volume":"19","author":"Leroux","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"i39","DOI":"10.1093\/jac\/dkx032","article-title":"Invasive mould infections in the ICU setting: Complexities and solutions","volume":"72","author":"Bassetti","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MCC.0000000000000230","article-title":"Fungal infections in the ICU: Advances in treatment and diagnosis","volume":"21","author":"Tumbarello","year":"2015","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13054-018-2023-z","article-title":"Fungal infections in adult patients on extracorporeal life support","volume":"22","author":"Cavayas","year":"2018","journal-title":"Crit. Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13054-014-0722-7","article-title":"Epidemiology of invasive aspergillosis in critically ill patients: Clinical presentation, underlying conditions, and outcomes","volume":"19","author":"Taccone","year":"2015","journal-title":"Crit. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/jac\/dkab012","article-title":"Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"76","author":"Dreesen","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","article-title":"Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: A retrospective study","volume":"38","author":"Wauters","year":"2012","journal-title":"Intensive Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Arastehfar, A., Carvalho, A., Van De Veerdonk, F.L., Jenks, J.D., Koehler, P., Krause, R., Cornely, O.A., Perlin, D.S., Lass-Fl\u00f6rl, C., and Hoenigl, M. (2020). COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment. J. Fungi, 6.","DOI":"10.3390\/jof6020091"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/jcpt.12636","article-title":"Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients","volume":"42","author":"Hahn","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s00134-007-0606-2","article-title":"Potential drug sequestration during extracorporeal membrane oxygenation: Results from an ex vivo experiment","volume":"33","author":"Mehta","year":"2007","journal-title":"Intensive Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/jac\/dkp026","article-title":"Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"63","author":"Spriet","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12967-020-02381-1","article-title":"Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane\/tazobactam: An ex vivo and in vivo study","volume":"18","author":"Delmas","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Putowski, Z., Szczepa\u0144ska, A., Czok, M., and Krzych, \u0141. (2021). Veno-Venous Extracorporeal Membrane Oxygenation in COVID-19-Where Are We Now?. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18031173"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00134-008-1269-3","article-title":"Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation","volume":"35","author":"Ruiz","year":"2009","journal-title":"Intensive Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/03602532.2019.1632888","article-title":"Novel insights into the complex pharmacokinetics of voriconazole: A review of its metabolism","volume":"51","author":"Schulz","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/FTD.0b013e31815c1672","article-title":"The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient","volume":"30","author":"Quintard","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mathieu, A., Thiboutot, Z., Ferreira, V., Benoit, P., Grandjean Lapierre, S., H\u00e9tu, P.O., and Halwagi, A. (2021). Voriconazole Sequestration During Extracorporeal Membrane Oxygenation for Invasive Lung Aspergillosis: A Case Report. ASAIO J.","DOI":"10.1097\/MAT.0000000000001427"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/FTD.0b013e3181898b0c","article-title":"Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation","volume":"30","author":"Antonius","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Peterson, E.L., Chittick, P.J., and Richardson, C.L. (2020). Decreasing voriconazole requirement in a patient after extracorporeal membrane oxygenation discontinuation: A case report. Transpl. Infect. Dis. Off. J. Transplant. Soc., e13545.","DOI":"10.1111\/tid.13545"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3389\/fped.2020.00468","article-title":"Sequestration of Voriconazole and Vancomycin Into Contemporary Extracorporeal Membrane Oxygenation Circuits: An In Vitro Study","volume":"8","author":"Raffaeli","year":"2020","journal-title":"Front. Pediatr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/0267659120937906","article-title":"Oxygenator impact on voriconazole in extracorporeal membrane oxygenation circuits","volume":"35","author":"Cies","year":"2020","journal-title":"Perfusion"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13054-018-2285-5","article-title":"The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation","volume":"22","author":"Winiszewski","year":"2018","journal-title":"Crit. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2009.12.021","article-title":"Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: An observational study","volume":"35","author":"Myrianthefs","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1128\/AAC.00251-13","article-title":"Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies","volume":"57","author":"Hoenigl","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bcpt.13465","article-title":"Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy","volume":"127","author":"Li","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/jcpt.12817","article-title":"Impact of voriconazole plasma concentrations on treatment response in critically ill patients","volume":"44","author":"Ruiz","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12941-017-0235-8","article-title":"Voriconazole and posaconazole therapeutic drug monitoring: A retrospective study","volume":"16","author":"Yi","year":"2017","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2146\/ajhp150372","article-title":"Voriconazole concentration monitoring at an academic medical center","volume":"73","author":"Sebaaly","year":"2016","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_30","unstructured":"Lewis, R., Br\u00fcggemann, R., Padoin, C., Maertens, J., Marchetti, O., Groll, A., Joneson, E., and Arendrup, M. (2021, May 17). Triazole Antifungal Therapeutic Drug Monitoring. ECIL 6 Meeting 2015. Available online: http:\/\/www.ecil-leukaemia.com\/telechargements2015\/ECIL6-Triazole-TDM-07-12-2015-Lewis-R-et-al.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00002480-200301000-00007","article-title":"Plasma concentrations of midazolam in neonates receiving extracorporeal membrane oxygenation","volume":"49","author":"Mulla","year":"2003","journal-title":"ASAIO J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zurl, C., Waller, M., Schwameis, F., Muhr, T., Bauer, N., Zollner-Schwetz, I., Valentin, T., Meinitzer, A., Ullrich, E., and Wunsch, S. (2020). Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations. J. Fungi, 6.","DOI":"10.3390\/jof6020090"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/phar.2348","article-title":"Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation","volume":"40","author":"Zhao","year":"2020","journal-title":"Pharmacotherapy"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/7\/1543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:32:31Z","timestamp":1760164351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/7\/1543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["microorganisms9071543"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms9071543","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]}}}